home / stock / xynpw / xynpw quote
Last: | $0.035 |
---|---|
Change Percent: | 0.0% |
Open: | $0.035 |
Close: | $0.035 |
High: | $0.035 |
Low: | $0.035 |
Volume: | 2,500 |
Last Trade Date Time: | 06/16/2021 04:42:14 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.035 | $0.035 | $0.035 | $0.035 | $0.035 | 2,500 | 06-16-2021 |
$0.0277 | $0.02767 | $0.0277 | $0.0277 | $0.0277 | 500 | 06-11-2021 |
$0.035 | $0.035 | $0.035 | $0.035 | $0.0313 | 34,401 | 06-09-2021 |
$0.0351 | $0.0385 | $0.0351 | $0.045 | $0.035 | 29,948 | 06-08-2021 |
$0.035 | $0.035 | $0.035 | $0.035 | $0.035 | 350 | 06-02-2021 |
$0.0481 | $0.0481 | $0.0481 | $0.0481 | $0.0481 | 230 | 05-31-2021 |
$0.0481 | $0.0481 | $0.0481 | $0.0481 | $0.0481 | 230 | 05-28-2021 |
$0.066 | $0.06562 | $0.066 | $0.066 | $0.0656 | 900 | 05-27-2021 |
$0.066 | $0.077 | $0.066 | $0.077 | $0.066 | 2,200 | 05-24-2021 |
$0.036 | $0.026 | $0.036 | $0.036 | $0.026 | 3,584 | 05-19-2021 |
$0.036 | $0.078 | $0.036 | $0.078 | $0.036 | 20,198 | 05-14-2021 |
$0.072 | $0.072 | $0.072 | $0.072 | $0.072 | 5,156 | 05-13-2021 |
$0.0428 | $0.041 | $0.0428 | $0.052 | $0.035 | 13,512 | 05-12-2021 |
$0.072 | $0.072 | $0.072 | $0.072 | $0.072 | 1,000 | 05-07-2021 |
$0.051 | $0.051 | $0.051 | $0.051 | $0.051 | 8,900 | 05-06-2021 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 312 | 04-28-2021 |
$0.08 | $0.035 | $0.08 | $0.08 | $0.035 | 11,100 | 04-26-2021 |
$0.088 | $0.0645 | $0.088 | $0.088 | $0.0645 | 9,623 | 04-21-2021 |
$0.041 | $0.041 | $0.041 | $0.041 | $0.041 | 3,000 | 04-14-2021 |
$0.069 | $0.094 | $0.069 | $0.094 | $0.0675 | 340 | 04-12-2021 |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc Warrants (15/05/2024) Company Name:
XYNPW Stock Symbol:
OTCMKTS Market:
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...